- Home
- WYY vs ACRV Comparison
WYY vs ACRV Comparison
Compare WYY & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- ACRV
- Stock Information
- Founded
- WYY 1991
- ACRV 2018
- Country
- WYY United States
- ACRV United States
- Employees
- WYY N/A
- ACRV N/A
- Industry
- WYY EDP Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- WYY Technology
- ACRV Health Care
- Exchange
- WYY Nasdaq
- ACRV Nasdaq
- Market Cap
- WYY 48.9M
- ACRV 47.8M
- IPO Year
- WYY 1998
- ACRV 2022
- Fundamental
- Price
- WYY $5.51
- ACRV $1.87
- Analyst Decision
- WYY Strong Buy
- ACRV Buy
- Analyst Count
- WYY 3
- ACRV 6
- Target Price
- WYY $8.00
- ACRV $17.75
- AVG Volume (30 Days)
- WYY 50.9K
- ACRV 482.4K
- Earning Date
- WYY 11-12-2025
- ACRV 11-12-2025
- Dividend Yield
- WYY N/A
- ACRV N/A
- EPS Growth
- WYY N/A
- ACRV N/A
- EPS
- WYY N/A
- ACRV N/A
- Revenue
- WYY $144,421,640.00
- ACRV N/A
- Revenue This Year
- WYY $9.19
- ACRV N/A
- Revenue Next Year
- WYY $13.16
- ACRV $805.34
- P/E Ratio
- WYY N/A
- ACRV N/A
- Revenue Growth
- WYY 16.25
- ACRV N/A
- 52 Week Low
- WYY $2.19
- ACRV $1.05
- 52 Week High
- WYY $6.25
- ACRV $8.74
- Technical
- Relative Strength Index (RSI)
- WYY 55.14
- ACRV 58.29
- Support Level
- WYY $5.37
- ACRV $1.69
- Resistance Level
- WYY $5.86
- ACRV $2.02
- Average True Range (ATR)
- WYY 0.28
- ACRV 0.14
- MACD
- WYY -0.00
- ACRV -0.01
- Stochastic Oscillator
- WYY 60.60
- ACRV 55.17
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.